Effectiveness of Dermylex(TM) supported by new results as Psoriasis Month kicks off across Canada

    Complemented by topical treatment, Dermylex(TM) may accelerate relief

    TORONTO, Oct. 1 /CNW/ - Jamieson Laboratories, Canada's leading
manufacturer of natural health products, today announced that a post-marketing
survey conducted on patients suffering from psoriasis shows that the use of
Dermylex(TM) may benefit patients already using topical medication
(corticosteroids and vitamin-D derivatives).
    The survey, conducted by Canadian health sciences and technology firm
Advitech Inc. ("Advitech") (TSX Venture Exchange: AVI), the company that
developed Dermylex, concluded that using Dermylex with topical medication may
create a synergistic effect and improve overall treatment efficacy results.
Therefore, Dermylex(TM) might act as an adjuvant to topical medication.
    These observations arise from a study by Advitech in which Dermylex users
were invited to provide their own evaluation and comment on the results
obtained with Dermylex, whether taken alone or part of a concomitant treatment
for psoriasis. In the questionnaire, psoriasis severity was quantified by
means of an intensity scale.
    "This new data provides Advitech and its commercial partners with
important information on treatment strategies and alternatives. Adding
Dermylex to a topical medication treatment appears to reduce psoriasis
severity," said Dr. Christina Juneau, Vice-President of Research and
Development, Advitech Inc. "Advitech will continue to gather and monitor
additional data and results from this post-marketing study in order to develop
therapeutic strategies for Dermylex(TM) users."
    Distributed exclusively by Jamieson Laboratories in Canada, Dermylex is a
patented blend of bioactive peptides from a natural source, with properties
that have been rigorously demonstrated through scientific studies. It acts as
an immune system regulator in auto-immune diseases such as psoriasis. During
clinical trials, patients who responded to Dermylex(TM) generally began to see
an improvement within 56 days. Dermylex is not a topical treatment, but a
tablet taken orally. This makes treatment more convenient. It is also a
product of natural origin. Its effectiveness has been demonstrated using the
same rigorous parameters as is used for pharmaceuticals, but it features the
safety profile of natural health products. Psoriasis is a non-contagious
chronic skin disease that strikes an estimated one million Canadians and
affects close to half of the Canadian population. Psoriasis is characterized
by patches of red, inflamed skin that are covered with a flaky, silvery
scaling. These patches, or lesions, generally appear on the scalp, elbows,
hands, knees, lower back, and buttocks and can often be itchy and painful.
Psoriasis is caused by an immune system disorder that affects skin cell
activity. Dermylex retails for $59.99 for 60 tablets. For more information
please visit www.dermylex.com.
    October is Psoriasis Awareness month in Canada and will culminate on
October 29 with World Psoriasis Day.

    About Advitech Inc.

    Advitech is a health sciences and technology company with a mission to
discover and commercialize proprietary and evidence-based natural health
products. Effective and safe, these products play a role in the prevention of
Immune-mediated inflammatory disorders, such as psoriasis and inflammatory
bowel disease.

    About Dermylex(TM)

    Dermylex(TM), developed by Advitech, is an oral natural health product
formulated to improve mild-to-moderate psoriasis symptoms. Two clinical
trials, one of them a multi-center, double-blind, placebo-controlled trial
with 84 patients for 112 days, clinically proved the efficacy and safety of
Dermylex(TM) for that type of psoriasis. Dermylex(TM) is currently available
in Canada and will soon be available in the U.S. (as BioDerm), and in France
and Belgium (as Psopax).

    About Psoriasis Society of Canada

    The Psoriasis Society of Canada is a national organization dedicated to
the people who have psoriasis. The society is a registered, charitable
organization and assists those who have psoriasis by providing information on
treatment, programs and services. For more information please call

    About Jamieson Laboratories
    Established in 1922, Jamieson Laboratories is Canada's largest
manufacturer and distributor of advanced natural health care products.
Jamieson's state-of-the-art pharmaceutical manufacturing laboratories are
located in Windsor, Ontario. The company is a world leader in the vitamin and
nutrition industry, exporting to more than 50 countries including the United
States, China, Japan, Hong Kong, Korea and Singapore. For more information,
please visit the Jamieson Laboratories website at www.jamiesonlabs.com or call
1 800 265-5088.

For further information:

For further information: Stephanie Blok, Manager of Public Relations,
Jamieson Laboratories, (416) 960-0052, Ext. 2714, sblok@jamiesonlabs.com

Organization Profile

Jamieson Laboratories

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890